184 related articles for article (PubMed ID: 18657104)
1. Long-term cost-effectiveness of pioglitazone versus placebo in addition to existing diabetes treatment: a US analysis based on PROactive.
Valentine WJ; Tucker D; Palmer AJ; Minshall ME; Foos V; Silberman C;
Value Health; 2009; 12(1):1-9. PubMed ID: 18657104
[TBL] [Abstract][Full Text] [Related]
2. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK.
Valentine WJ; Bottomley JM; Palmer AJ; Brändle M; Foos V; Williams R; Dormandy JA; Yates J; Tan MH; Massi-Benedetti M;
Diabet Med; 2007 Sep; 24(9):982-1002. PubMed ID: 17593245
[TBL] [Abstract][Full Text] [Related]
3. A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.
St Charles M; Minshall ME; Pandya BJ; Baran RW; Tunis SL
Curr Med Res Opin; 2009 Jun; 25(6):1343-53. PubMed ID: 19419339
[TBL] [Abstract][Full Text] [Related]
4. Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States.
Guillermin AL; Lloyd A; Best JH; DeYoung MB; Samyshkin Y; Gaebler JA
J Med Econ; 2012; 15(4):654-63. PubMed ID: 22369345
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting.
Brändle M; Goodall G; Erny-Albrecht KM; Erdmann E; Valentine WJ
Swiss Med Wkly; 2009 Mar; 139(11-12):173-84. PubMed ID: 19330561
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand.
Permsuwan U; Chaiyakunapruk N; Dilokthornsakul P; Thavorn K; Saokaew S
Appl Health Econ Health Policy; 2016 Jun; 14(3):281-92. PubMed ID: 26961276
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.
Palmer JL; Gibbs M; Scheijbeler HW; Kotchie RW; Nielsen S; White J; Valentine WJ
Adv Ther; 2008 Aug; 25(8):752-74. PubMed ID: 18704282
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of switching to biphasic insulin aspart 30 from human insulin in patients with poorly controlled type 2 diabetes in South Korea.
Lee KH; Seo SJ; Smith-Palmer J; Palmer JL; White J; Valentine WJ
Value Health; 2009; 12 Suppl 3():S55-61. PubMed ID: 20586983
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of thiazolidinediones in uncontrolled type 2 diabetic patients receiving sulfonylureas and metformin in Thailand.
Chirakup S; Chaiyakunapruk N; Chaikledkeaw U; Pongcharoensuk P; Ongphiphadhanakul B; Roze S; Valentine WJ; Palmer AJ
Value Health; 2008 Mar; 11 Suppl 1():S43-51. PubMed ID: 18387067
[TBL] [Abstract][Full Text] [Related]
10. Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analysis in a German setting.
Roze S; Valentine WJ; Evers T; Palmer AJ
Curr Med Res Opin; 2006 Jul; 22(7):1415-24. PubMed ID: 16834840
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a german statutory healthcare perspective.
Neeser K; Lübben G; Siebert U; Schramm W
Pharmacoeconomics; 2004; 22(5):321-41. PubMed ID: 15061682
[TBL] [Abstract][Full Text] [Related]
12. Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US.
Tunis SL; Minshall ME; St Charles M; Pandya BJ; Baran RW
Curr Med Res Opin; 2008 Nov; 24(11):3085-96. PubMed ID: 18826750
[TBL] [Abstract][Full Text] [Related]
13. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
Ray JA; Boye KS; Yurgin N; Valentine WJ; Roze S; McKendrick J; Tucker DM; Foos V; Palmer AJ
Curr Med Res Opin; 2007 Mar; 23(3):609-22. PubMed ID: 17355742
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective.
Viriato D; Calado F; Gruenberger JB; Ong SH; Carvalho D; Silva-Nunes J; Johal S; Viana R
J Med Econ; 2014 Jul; 17(7):499-507. PubMed ID: 24708176
[TBL] [Abstract][Full Text] [Related]
15. Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US.
Samyshkin Y; Guillermin AL; Best JH; Brunell SC; Lloyd A
J Med Econ; 2012; 15 Suppl 2():6-13. PubMed ID: 22793669
[TBL] [Abstract][Full Text] [Related]
16. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.
Gao L; Zhao FL; Li SC
Int J Technol Assess Health Care; 2012 Oct; 28(4):436-44. PubMed ID: 23006540
[TBL] [Abstract][Full Text] [Related]
17. A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK.
Tilden DP; Mariz S; O'Bryan-Tear G; Bottomley J; Diamantopoulos A
Pharmacoeconomics; 2007; 25(1):39-54. PubMed ID: 17192117
[TBL] [Abstract][Full Text] [Related]
18. Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis.
Palmer AJ; Tucker DM
Prim Care Diabetes; 2012 Jul; 6(2):109-21. PubMed ID: 22153888
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.
Valentine WJ; Palmer AJ; Lammert M; Langer J; Brändle M
Clin Ther; 2011 Nov; 33(11):1698-712. PubMed ID: 22018679
[TBL] [Abstract][Full Text] [Related]
20. Pioglitazone and vitamin E for nonalcoholic steatohepatitis: a cost utility analysis.
Mahady SE; Wong G; Craig JC; George J
Hepatology; 2012 Dec; 56(6):2172-9. PubMed ID: 22707355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
